ClinicalTrials.gg
RecruitingNCT06561360Updated Nov 17, 2026

A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL)

A Phase 2 interventional study of Vemurafenib and Obinutuzumab in Hairy Cell Leukemia, sponsored by Memorial Sloan Kettering Cancer Center. Recruiting at 10 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Memorial Sloan Kettering Cancer Center · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2024; still recruiting 2 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
86
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 199 studies in Leukemia, Hairy Cell with a site in United States — 11 open to participants now, 24 under way, none of them phase 3. Leukemia, Hairy Cell · United States.

Planned enrollment
29th of 138
86 · median 37
Started
2024
with 2 others
Phase 2
51 of 199
3 open now
Primary completion
2027-09
later than 12 of 22 live
Registered
197th of 199
by date
Lead sponsor
9 of 199
Memorial Sloan Kettering Cancer Center

Among the 199 studies in Leukemia, Hairy Cell with a site in United States, this one is the 29th largest by planned enrollment of the 138 interventional ones that give a count, is one of 3 that started in 2024, is one of 51 in phase 2, reaches primary completion later than 12 of the 22 other live ones, and was the 197th registered.

Leukemia, Hairy Cell

237 studies on the registry are indexed under Leukemia, Hairy Cell; 18 are open to participants now.

Browse Leukemia, Hairy Cell studies →

Open to participants now

11 of the 199 studies in Leukemia, Hairy Cell with a site in United States are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 14 Leukemia, Hairy Cell studies recruiting now, 12 (86%) set no upper age limit and none (0%) stop at 75 or younger; none take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 199 studies in Leukemia, Hairy Cell with a site in United States, or all of them as a file.
02

Study summary

The researchers are doing this study to compare the safety of vemurafenib in combination with obinutuzumab to the standard of approach of cladribine in combination with rituximab. The researchers will look at which treatment causes fewer or milder side effects. Researchers think vemurafenib and obinutuzumab (non-chemotherapy drugs) may cause fewer side effects compared with the usual approach of chemotherapy drugs. They will also compare the two approaches to see which approach is more effective at eliminating cancer cells.

03

Conditions studied

  • Hairy Cell Leukemia

Browse trials for

Keywords

  • Vemurafenib
  • Obinutuzumab
  • Cladribine
  • Rituximab
  • 24-160
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients must be ≥ 18 years of age
  • confirmed classical HCL by the enrolling institution
  • Presence of BRAF V600E mutation as confirmed by PCR, NGS or immunohistochemistry. If patient is known to have negative BRAF mutation, repeat testing is advisable as well as discussion with the main study principal investigator.
  • Has not received any prior therapy for the disease
  • Patients who meet the standard treatment initiation criteria, as defined by ANC ≤1.0, ≤ 10.0 or ≤100K
  • performance status of 0 - 2
  • Acceptable pre-study organ function during screening as defined as:

    • Total ≤ 1.5 times the (ULN), except in patients with known Gilbert's syndrome who may be enrolled if direct bilirubin ≤ 3 x ULN);
    • (AST) and alanine aminotransferase (ALT) ≤ 2.5x ULN; and
    • Serum creatinine ≤ 1.5x ULN
  • (ECG) without evidence of ventricular arrhythmias or ischemia as determined by the investigator and a rate- interval (QTc, Bazett's formula) of \< 480 msec
  • For women of , agreement to the use of two acceptable methods of , including one barrier method, during the study and for 6 months after discontinuation of vemurafenib and cladribine, and 18 months after discontinuation of rituximab and obinutuzumab
  • For men with female partners of childbearing potential, agreement to use a latex condom and to advise their female partner to use an additional method of contraception during the study and for 6 months after discontinuation of vemurafenib
  • Negative serum pregnancy test within 7 days of commencement of treatment in women of childbearing potential

Exclusion criteria

Exclusion Criteria:

  • Have had previous treatment for HCL, including purine analogs, vemurafenib, rituximab, obinutuzumab, and other agents. Previous treatment with transfusions and other supportive care such as G-CSF and erythropoietin are allowed.
  • Known to any of the study drugs.
  • Patients with known long syndrome or uncorrectable electrolyte abnormalities
  • history of liver disease, including viral or other hepatitis, current alcohol abuse, or cirrhosis.
  • Presence of positive test results for virus (HBV), hepatitis B surface antigen (HBsAg) or (HCV) antibody

    ° Patients with occult or prior HBV infection (defined as positive total hepatitis B core antibody [HBcAb] and negative HBsAg) may be included if HBV DNA is undetectable. These patients must be willing to undergo monthly DNA testing and take HBV viral prophylaxis such as entecavir.

  • Known infection with or human T-cell leukemia virus 1 (HTLV-1)
  • Active uncontrolled infection, e.g. persistent bacteremia, supplemental oxygen or pressor supports, etc.
  • within 28 days of randomization
  • Patients with concurrent active as defined by malignancies requiring any therapy other than expectant observation or hormonal therapy, with the exception of squamous and basal cell carcinoma of the skin, in situ cervical cancer, adequately treated stage I/II cancer from which the patient is current in complete remission, or any other cancer from which the patient has been disease free for five years
  • Malabsorption syndrome or other condition that precludes enteral route of administration
  • Patients with HCL variant (as defined by absence of expression of CD25)
  • Pregnant or lactating, or intending to become pregnant during the study
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
86 participants (estimated)

Study arms

  • Experimental
    Vemurafenib plus Obinutuzumab

    Patients assigned to the study arm will receive vemurafenib orally twice daily (b.i.d.) continuously in cycles of 4 weeks (28 days) for a total of 4 cycles. Obinutuzumab will be administered concomitantly with vemurafenib starting at cycle 2 of treatment in cycles of 4 weeks. Obinutuzumab infusions will be administered on days 1, 8 and 15 during the cycle 2 and every 4 weeks during the cycle 3 and 4 of treatment.

    Drug: Vemurafenib · Drug: Obinutuzumab

  • Active comparator
    Standard treatment of Cladribine plus Rituximab

    Patients assigned to the SOC arm will receive cladribine IV on days 1-5 concurrently with rituximab IV per week for 8 times, i.e., weekly x8 from day 1.

    Drug: Cladribine · Drug: Rituximab

Interventions

  • Vemurafenib orally twice daily (b.i.d.) continuously in cycles of 4 weeks (28 days) for a total of 4 cycles.

  • Obinutuzumab will be administered concomitantly with vemurafenib starting at cycle 2 of treatment in cycles of 4 weeks.

  • Cladribine IV on days 1-5 concurrently with rituximab.

  • Rituximab on days 1-5 concurrently with rituximab.

06

What researchers measure

Primary outcomes

  1. incidences of ≥ grade 3 treatment-related toxicities

    per CTCAE v5.0 within first 6 months from the start of the treatment to account delayed toxicities of the treatments

    Time frame: within 6 months of treatment

Secondary outcomes

  1. complete remission

    Response will be determined by the Consensus Resolution response criteria. Complete response (CR) * A morphological absence of hairy cells in the blood and bone marrow * A normalization of any organomegaly and cytopenias

    Time frame: 2 years

  2. partial response

    Partial response (PR) °A normalization of cytopenias °≥50% reduction in organomegaly and bone marrow hairy cells.

    Time frame: 2 years

07

Study locations

8 of 10 sites recruiting
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02115, United States
    Not yet recruiting
    • Eric Winer, MD · Contact(617) 632-6876
  • Mayo Clinic Cancer Center
    Rochester, Minnesota 55905, United States
    Not yet recruiting
    • Sameer Parikh, M.B.B.S. · Contact507-218-0772
  • Memorial Sloan Kettering at Basking Ridge (All Protocol Activities)
    Basking Ridge, New Jersey 07920, United States
    Recruiting
    • Jae Park, MD · Contact646-608-3743
  • Memorial Sloan Kettering Monmouth (Limited Protocol Activities)
    Middletown, New Jersey 07748, United States
    Recruiting
    • Jae Park, MD · Contact646-608-3743
  • Memorial Sloan Kettering Bergen (Limited Protocol Activities)
    Montvale, New Jersey 07645, United States
    Recruiting
    • Jae Park, MD · Contact646-608-3743
  • Memorial Sloan Kettering Cancer Commack - Suffolk (Limited Protocol Activities)
    Commack, New York 11725, United States
    Recruiting
    • Jae Park, MD · Contact646-608-3743
  • Memorial Sloan Kettering Westchester (All Protocol Activities)
    Harrison, New York 10604, United States
    Recruiting
    • Jae Park, MD · Contact646-608-3743
  • Memorial Sloan Kettering Cancer Center (All Protocol Activities)
    New York, New York 10065, United States
    Recruiting
    • Jae Park, MD · Contact646-608-3743
  • Memorial Sloan Kettering Nassau (Limited Protocol Activities)
    Uniondale, New York 11553, United States
    Recruiting
    • Jae Park, MD · Contact646-608-3743
  • Ohio State University
    Columbus, Ohio 43210, United States
    Recruiting
    • Seema Bhat, MD · Contact614-293-3196
08

References and documents

Individual participant data

Plan to share: Yes — Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2024 (actual). Primary completion is estimated for Sep 2027, 36 months after the start.

Of 22 phase 2 interventional studies under Leukemia, Hairy Cell, half reached primary completion within 111 months of starting (the median), counting those still running; a quarter within 64 and three quarters within 149. This study's planned 36 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 13, 2024
First posted
Aug 20, 2024
StartActual
Sep 9, 2024
Primary completionEst.
Sep 9, 2027
CompletionEst.
Sep 9, 2027
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Site contacts
Changed at 1 site. See the sites
Show the site
  • Ohio State University · Columbus, United StatesContact •••3196→•••3196Contact removed (no phone or email listed)
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Ohio State University · Columbus, United StatesContact •••3196→•••3196Contact removed (no phone or email listed)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06561360
Collaborators
Genentech, Inc.
Responsible party
Sponsor
First posted
Aug 20, 2024
Start date
Sep 9, 2024
Primary completion
Sep 9, 2027 (estimated)
Completion
Sep 9, 2027 (estimated)
Last update
Nov 17, 2026

Study contacts

Jae Park, MD
Contact
parkj6@mskcc.org
646-608-3743
Mark Geyer, MD
Contact
646-608-3745
Jae Park, MD
principal investigator · Memorial Sloan Kettering Cancer Center

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Vemurafenib · Obinutuzumab

Start the discussion